Current Conatus Trials

pipeline

Investigational Medicine

Conatus Pharmaceuticals medicine, emricasan (IDN-6556), is considered investigational, meaning that it is being evaluated in clinical trials and is not yet approved for use by regulatory authorities. Approval by regulatory authorities around the world, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), is the means to make our medicines available to the patient.

How to Access Conatus' Emricasan

To learn more about Conatus' current clinical programs, you can read our Clinical Development section and visit www.clinicaltrials.gov.

A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV

A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis (ENCORE-NF)

Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension (ENCORE-PH)